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ABSTRACT
Objective: To present the results of
percutaneous endoscopic gastrostomy (PEG), 
which has been an alternative method to 
conventional surgical gastrostomy for the last 20 
years. PEG is one of the gastrostomy methods 
used for patients unable to take food orally.
Patients and Methods: Between January 1996 
and July 2000, 50 consecutive patients in need of 
enteral feeding for more than four weeks and 
undergoing PEG with 20 Fr tube by pull 
technique were retrospectively evaluated in 
terms of indication, complications, durability of 
tube, and mortality. The assessment of wound 
infection was conducted according to the criteria 
developed by Jain and Shapiro.
Results: A PEG was successfully positioned in 
50 of the 52 referred patients (96%). Of the 50 
cases 26 (52%) were men and 24 (48%) women 
with the median age of 63 years (range 2 to 88 
years). Indications for PEG placement were 
cerebrovascular accident in 20, brain tumors in 
11, subarachnoidal hemorrhage in 9, several 
neurologic disorders in 5 (2 infections, 2 
Parkinson’s disease, 1 Alzheimer’s disease), 
head injury in 3, iatrogenic in 1 (esophago- 
cutaneous fistula), and hypoxic encephalopathy 
in 1. The durability of the tube was a median of
217.5 days (range 9 to 1669 days). In 9 patients 
the tube was removed with a median of 158.5 
days (range 35 to 427 days) and then oral 
feeding was started. The tube was changed 
in 7 patients who had tube dysfunction 
because of clogging, porosity or fracture with a 
median interval of 122 days (range 35 to 1252 
days). Of these patients, 2 needed replacement 
tube insertion twice and 3 three times. Two (4%) 
cases had minor complications (wound infection) 
during the the first 30 days. During total follow­
up, two wound infections, one buried bumper 
syndrome, and one aspiration pneumonia 
developed. The last patient underwent JETPEG 
which was performed by introducing a 10 Fr 
jejunal tube through the 20 Fr PEG opening. 
Total follow-up was 41.8 patient-years with a 
procedure-related mortality of 0%, 30-day 
mortality of 8% (4/50), and overall mortality of 
32% (16/50). The mortality rate was 63.6% (7/11) 
for patients who had brain tumor and 23% (9/39) 
for the rest.
Conclusion: PEG is a minimally invasive 
gastrostomy method with low morbidity and 
mortality rates, easy to follow-up, easy to replace 
when clogged.
Key W ords: Percutaneous endoscopic 
gastrostomy, Enteral feeding.
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INTRODUCTION
Percutaneous endoscopic gastrostomy (PEG) is 
an alternative to traditional surgical methods for 
creating a feeding gastrostomy. Since its first 
description by Gauderer and Ponsky (1) in 1980, 
PEG has become a widely accepted means of 
providing enteral alimentation. The most 
common indication for PEG tube placement is to 
provide access to a functioning gastrointestinal 
tract for long-term enteral nutrition (2). This term 
is usually accepted as a minimum of 4 weeks (3). 
Patients in this group often have neurologic 
disorders and neoplasms of the head, neck, and 
esophagus. Other applications of PEG include 
decompression in patients with malignant 
carcinomatosis and intestinal obstruction, 
treatment of gastric volvulus, recirculation of bile, 
accessing the stomach for endoscopic or surgical 
instrumentation, administration of unpalatable 
medications to pediatric patients, and provision 
of nutrition to patients in various hypercatabolic 
states (such as those with Crohn's disease and 
severe burns) (2,4,5). Absolute contraindications 
to PEG tube placement include a limited life 
expectancy, inability to pass the endoscope 
through the esophagus, and peritonitis (6,7). 
Relative contraindications include massive 
ascites, coagulopathy, portal hypertension, 
peritoneal dialysis, hepatomegaly, large hiatal 
hernia, prior subtotal gastrectomy, morbid 
obesity, anorexia nervosa, and infiltrative or 
malignant disorders of the stomach (2,7-9).
PEG can be performed by the pull method, the 
introducer method, or the push method (2). 
However, the “pull method” has changed little 
since its original description and remains the 
most popular method of PEG tube placement
(1,2,10). Major complications of PEG include 
peritonitis, hemorrhage, aspiration, peristomal 
wound infection, buried bumper syndrome, and 
gastrocolic fistula (2,11,12). The morbidity rate is 
given as approximately 3% in large series
(13,14). These complications are uncommon, but 
when they occur they result in death in 25% of 
the patients. One of the most common 
complications of PEG is aspiration especially in 
patients who have preexisting gastro-esophageal 
reflux disease. JETPEG (introducing a thinner 
jejunal tube distally to Treitz’s ligament through 
the PEG) has recently become more popularized 
to avoid this complication (3,4,15).
PATIENTS AND METHODS
Patients:
Between January 1996 and July 2000, 52 
patients were referred from Marmara University 
Institute of Neurologic Sciences to our 
endoscopy unit for the placement of a PEG tube. 
Of the 52 patients, a PEG was successfully 
positioned in 50. Patients, or in the case of 
complete incapacitation, their legally responsible 
relatives, were informed about the possibilities 
and risks associated with PEG and written 
informed consent was obtained from each of 
them.
The PEG Technique:
All patients received antibiotic prophylaxis, 1 g 
ceftriaxone (Rocephin®, Roche) intravenously, 
30 minutes before PEG placement and weight- 
and age-adapted premedication (up to 100 mg 
pethidine, or 5 mg midazolam). Local disinfection 
of the oropharyngeal cavity was not done. The 
patients’ abdomen was thoroughly disinfected 
from the costal margin to the navel.
PEG placement was applied using the “pull 
method” (16). After preparation of the abdomen, 
a complete upper gastrointestinal endoscopy 
was performed. The stomach was then 
insufflated, resulting in close opposition of the 
stomach to the abdominal wall. A local anesthetic 
(Jetocaine®, Adeka) was infiltrated into the skin 
in the midepigastrium where there was maximum 
transillumination and indentation of the gastric 
lumen by an examining finger. After performing 
a 5 mm skin incision, a 16-gauge angiocath was 
inserted into the gastric lumen under direct 
endoscopic observation. A guidewire was 
threaded through the angiocath and grasped 
with a snare. After the endoscope and the 
snare grasping the guidewire were withdrawn 
from the mouth at the same time, the tapered end 
of the gastrostomy tube was secured to the 
guidewire and the PEG tube guidewire unit was 
placed in the stomach by pulling the end of 
the guidewire exiting the skin incision. The 
internal bumper remained in the gastric lumen. 
The external bumper was subsequently used 
to secure the PEG tube in place. A control 
endoscopy was done to be sure of the success of 
the procedure and to check for any 
complications.
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After PEG tube placement, both the patient and 
the family members as well were instructed by 
nurses concerning the system of nutrition and the 
use of the feeding pump. Patients were allowed 
to return home once they had mastered the 
implementation of the system. Nutrition was 
initiated 4-24 hours after complication-free PEG 
placement, and the level was increased 
continuously over several days up to individually 
adequate feeding rate, in order to minimize the 
side effects of tube-based nutrition.
Table III. Indications for PEG tube placement.
Cerebrovascular accident 20
Brain tumor 11
Subarachnoidal hemorrhage 9
Miscallaneous neurologic disorders 5
Infectious 2
Parkinson’s disease 2
Alzheimer's disease 1
Head injury 3
Iatrogenic (esophago-cutaneous fistula) 1
Hypoxic encephalopathy 1
Follow-up and Evaluation of Peristomal 
Wound Infection:
All the patients were followed-up daily for the first 
week, then weekly for the first month, and 
monthly thereafter. Discharged patients were 
also followed-up monthly by telephone inquiries. 
For the first 7 days after PEG tube placement, 
the wound dressing at the site of puncture was 
renewed daily by the same team and checked for 
possible infection. The assessment of wound 
infection was conducted on a daily basis 
according to the criteria developed by Jain et al. 
(17) and Shapiro et al. (18), as shown in Table I. 
Patients were defined as having minor or major 
complications according to their daily score 
(Table II).
RESULTS
In 2 of 52 patients (4%), PEG placement was not 
possible due to failure to achieve transillumination
Table I. The scale for the assessment of local wound Infection.
0 1 2 3 4
Erythema no <5 mm 6-10 mm 11-15 mm >15 mm
Induration no <10 mm 11-15 mm >15 mm
Exudate no serous sero-sanguineous sanguineous purulent
Table II. Classification of Infectious complications according to 
the patients' dally score.
Dally score
Grade I less then 2
Grade II between 3 and 8
Grade III over 8 or manifest purulent exudate
Grade IV Peritonitis or had to have PEG removed
Grade l-ll-lll minor complication
Grade IV major complication
or “safe tract” technique explained below. Of the 
50 cases, 26 (52%) were men, 24 (48%) women 
with the median age of 63 years (range 2 to 88 
years). The indications for PEG tube placement 
are shown in Table III. The durability of the tube 
was a median of 217.5 days (range 9 to 1669 
days). In 9 (18%) patients the tube was removed 
with a median of 158.5 days (range 35 to 427 
days) because they were able to return to oral 
feeding. The tubes were changed in 7 (14%) 
patients who had tube dysfunction due to 
clogging, porosity or fracture with a median 
interval of 122 days (range 35 to 1252 days). Of 
those patients, 2 needed replacement tube 
insertion twice, 3 three times. Minor 
complications (wound infection) developed in 2 
(4%) patients during first 30 days. Neither 
hemorrhage nor major complication was seen in 
all patients. During total follow-up 4 (8%) 
complications (2 wound infections, 1 buried 
bumper syndrome, and 1 aspiration pneumonia) 
developed. The patients who had grade ll-lll 
wound infection were successfully treated by 
close wound care and antibiotics. Buried bumper 
syndrome was recognized incidentally when the 
patient underwent tube replacement because of 
porosity and clogging. Endoscopic finding was 
mucosal dimpling to non-visualization of the 
internal bolster. The problem was solved by 
dissecting the buried appliance from the 
abdominal wall under local anesthesia and a 15 
Fr replacement tube inserted into the stomach 
from the same site. The patient who had 
aspiration pneumonia underwent JETPEG for the 
solution of the problem. JETPEG was performed 
by introducing a 10 Fr jejunal tube through the 20 
Fr PEG tube, and placing it distally to the Treitz’s 
ligament. Total follow-up was 41.8 patient-years. 
Procedure related mortality was 0%, 30-day 
mortality 8% (4/50), and overall mortality 32%
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(16/50). The mortality rate was 63.6% (7/11) for 
patients who had brain tumors and 23% (9/39) 
for the rest.
D IS C U S S IO N
Nutritional support can be quite challenging. The 
advantages of enteral nutrition over parenteral 
nutrition are well known and include lower cost, 
increased safety, better patient tolerance, 
maintenance of structural gastrointestinal 
integrity, and increased resistance against 
infection (19,20). Several advantages of the 
percutaneous approach compared to operative 
gastrostomy are the use of local anesthesia, 
decreased procedure time, ability to perform the 
procedure in the endoscopy suite, decreased 
cost and earlier feeding after placement (3,21). 
PEG for enteral nutrition has become widespread 
and offers distinct advantages with regard to cost 
and a low level of complications compared with 
parenteral nutrition (22,23). PEG proved to be a 
very safe and reliable method in the scope of 
literature. On the other hand, short- and long­
term prospective studies have demonstrated the 
superiority of a PEG over nasogastric feeding 
tubes in patients with dysphagia due to chronic 
neurologic disease (3,24-27).
The performance of a full diagnostic upper 
endoscopy is imperative before PEG tube 
placement (2). Patients scheduled for PEG tube 
placement may have endoscopic findings, such 
as peptic ulcer disease and gastric outlet 
obstruction that ultimately lead to major 
modifications in management or abandonment of 
the procedure. Wolfsen et al. (28) gave this rate 
as high as 36%. However, we did not find such 
endoscopic findings before starting the 
procedure in our patients. Although it has been 
suggested that if a point of resistance is felt 
between the 3rd and 6th cm marking on the PEG 
tube or if the internal bumper can be appreciated 
by finger palpation of the abdominal wall, repeat 
endoscopy is not necessary; we preferred to 
perform it in order to avoid any suspicion in the 
endoscopist's mind (29,30). Several of the early 
papers describe transillumination of the stomach 
prior to gastric puncture as being integral to the 
procedure (21,31). Larson et al. (32) describe a 
failure to transilluminate the stomach as being an 
absolute contraindication to PEG tube insertion.
However, it became a relative contraindication 
with pioneering the “safe tract technique” by 
Foutch et al. (33) and verifying in a retrospective 
series by Stewart and Hagan (34). When 
transillumination fails, we try the safe tract 
technique with gastric mucosal indentation which 
can be achieved by simple palpation, and then 
introduce 16-gauge angiocath into the stomach. 
This gives the safe way to gastric puncture. 
However, in our series, a PEG tube could not be 
positioned in two patients, even though both 
transillumination and the safe tract technique 
were used. In such circumstances, the other 
gastrostomy methods should be chosen instead 
of insisting on completion of the procedure.
The time interval between the PEG tube 
placement and feeding initiation is controversial. 
Some authors recommend 12-24 hours before 
initiating the PEG feeding, whereas others prefer 
4 hours of rest after PEG tube placement (2,22). 
In a randomized prospective trial of early versus 
delayed feeding after PEG, it has been 
suggested that early initiation of PEG feeding is 
safe, well tolerated, and reduces cost by 
decreasing hospital stay (35). We allowed to 
feeding 4-24 hours after PEG placement.
Antibiotic prophylaxis is recommended as a 
general measure in PEG (22). It has been shown 
that antibiotic prophylaxis significantly reduces 
the risk of peristomal wound infection associated 
with PEG insertion (22). Dormann et al. (36) have 
shown that a single dose of ceftriaxone 
administered 30 minutes before PEG 
significantly reduces local and systemic infective 
complications. We preferred ceftriaxone as a 
prophylactic antibiotic to avoid infectious 
complications. The wound infection rate of the 
present study was as low as 4% when compared 
to 5-30% of the studies in the literature (2,36).
Buried bumper syndrome occurs when excessive 
traction is applied to the PEG tube for an 
extended period. This results in ischemic 
necrosis of the gastric mucosa and migration of 
the internal bolster into the gastric or abdominal 
wall. It usually becomes apparent after 4 months 
of use (2). This complication developed in one 
case in our series, almost one year after the PEG 
tube placement. Treatment requires dissection of 
the buried appliance from the abdominal wall, 
and the same site can be used for placement of
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a second PEG or replacement tube. To prevent 
buried bumper syndrome, it is advisable to allow 
for an additional 1.5 cm between the external 
bumper of the PEG tube and the skin to minimize 
the risk of pressure necrosis (2).
Patients with gastroparesis and gastric atony, for 
instance neurosurgical trauma or with gastric 
outlet obstructions, are at risk of aspiration. 
Consistently, factors such as a history of 
aspiration (pneumonia), reflux esophagitis, age 
older than 70 years, absent swallowing, gag and 
cough reflexes and cerebrovascular accident 
emerge from published data as factors 
predisposing to aspiration (37,38). Despite many 
improvements in tube design and size, a 
tremendous controversy exists as to the use of a 
JETPEG (39). Opponents argue that the 
associated mortality and morbidity of a JETPEG 
tube together with the inability to protect against 
pulmonary complications and the high incidence 
of jejunal tube failure make its use unjustifiable 
(40,41). Those who advocated intestinal feeding 
have observed a substantial reduction in 
aspiration pneumonia and have accepted a high 
catheter failure (42). However, it has been shown 
in a recent study that JETPEG may reduce the 
aspiration risk in the compliant high-risk patients 
and those with ongoing or previously 
documented aspiration (3). In the same study, 
the catheter failure rate was 26.8% during 
extended follow-up, which was significantly lower 
than the reported 53% (3,40). In our series, we 
performed a JETPEG in one patient who had 
developed aspiration pneumonia during follow­
up.
To summarize, during the 20 years since its 
introduction, PEG has remained the benchmark 
for long-term enteral alimentation against which 
all other such innovative methods must be 
measured. JETPEG should be reserved for well- 
selected patients at risk of aspiration.
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